

Invitation to presentation of Xbrane Biopharma's interim report January – Juni 2020 on August 21, 2020.

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on August 21, 2020, at 10.00 a.m. CET. Xbrane will publish the company's interim report January – June 2020, on Friday August 21, 2020, at 8.00 a.m. CET.

Martin Åmark, CEO, and Susanna Helgesen, CFO, will present Xbrane and comment on the interim report January – June 2020, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below:

Standard international: +44 (0) 2071 928 338

UK (Local): +44 (0) 844 481 97 52

UK (Tollfree): 08 002 796 619

Sweden (Local): +46 (0) 850 692 180

Sweden (Toll Free): 020 012 51 60

US (Local): +1 646 741 31 67

US (Toll Free): +1 877 870 91 35

Confirmation Code: 4598698

Web link:

<https://edge.media-server.com/mmc/p/iacxcxxa>

Contacts

Martin Åmark, CEO/ IR

M: +46 (0) 763-093 777

E: martin.amark@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

Press Release
20 August 2020 13:30:00 CEST



Attachments

[Invitation to presentation of Xbrane Biopharma's interim report January – Juni 2020 on August 21, 2020.](#)